PULMONARY ARTERIAL HYPERTENSION

This study looks at the long-term safety of an inhaled medication called seralutinib for people with pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the arteries in the lungs. About 316 participants who finished a previous seralutinib …

This early study tests a small, permanent device called the V-Wave Interatrial Shunt in 9 people with severe pulmonary arterial hypertension (PAH). The device is placed in the heart during a minimally invasive procedure to create a small opening between the upper chambers, which …

This study is testing the safety and right dose of a drug called selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal is to find a dose that works like the adult version. The stu…

This study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH). About 138 children will receive either selexipag or a placebo, plus their usual medications. The main goal is to see if…

This phase 3 trial compares two doses of macitentan (75 mg vs 10 mg) in about 935 adults with pulmonary arterial hypertension. The goal is to see if the higher dose can delay serious events like hospitalization or death. Participants will be followed for several years.

This study is testing the long-term safety and tolerability of an inhaled treprostinil powder (TPIP) in people with pulmonary arterial hypertension (PAH). About 91 participants who completed earlier TPIP studies will receive the drug for up to several years. Researchers will moni…

This early-stage study by Pfizer tests a new drug called PF-07868489. First, it will be given to healthy volunteers to check safety and how the body processes it. Then, people with pulmonary arterial hypertension (PAH) will receive repeated doses over 24 weeks to see if it helps …

This study looks at the long-term safety of an inhaled drug called GB002 for people with pulmonary arterial hypertension (PAH), a serious lung condition. It includes 74 patients who already completed a previous GB002 study. Researchers will track side effects and measure how far …

This study tests a new drug, Oxacom®, in 200 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The drug is given in different doses to see if it can lower pressure in the lung's blood vessels better than a placebo. The goal…

This study is a patient registry that follows 300 adults with pulmonary arterial hypertension (PAH) who are starting or recently started Orenitram. Researchers will track how well patients tolerate the drug and how it affects their daily function and symptoms over 78 weeks. The g…

This study tests a new inhaled drug called L606 (liposomal treprostinil) in 28 adults with pulmonary arterial hypertension or PH-ILD. The goal is to see if it is safe and tolerable when taken twice daily, both short-term and over a year. Participants either switch from another in…

This study looks at the long-term safety of the drug ralinepag in people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who were in earlier ralinepag studies can join. The goal is to see if the drug remains s…

This study tests an implanted catheter and pump system that delivers Remodulin, a drug for pulmonary arterial hypertension (PAH), directly into the bloodstream. The goal is to see if this device is safe for long-term use. The trial includes 64 patients who already use the system.…

This study tests whether empagliflozin, a diabetes medicine, can improve right heart function in 78 adults with pulmonary arterial hypertension (PAH). Participants continue their usual PAH treatments and receive either empagliflozin or a placebo. The main goal is to see if the dr…

This study tests whether quickly starting and increasing a medication called treprostinil can lower blood pressure in the lungs and improve the heart's pumping ability in people with pulmonary arterial hypertension (PAH). The trial involves 52 adults with PAH and will measure cha…

This study looks at the long-term safety of a medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Participants from an earlier study can join and receive weight-based doses every 3 weeks. The main goal is to see if the medicine is safe and well-tole…

This study tests whether a 12-week program of exercise and diet counseling can improve insulin sensitivity and heart function in people with pulmonary arterial hypertension (PAH). The 34 participants have stable PAH and are already on standard medications. The goal is to see if l…

This Phase 2 trial tests whether satralizumab, an antibody that blocks IL-6 (a protein involved in inflammation), can improve blood flow in the lungs of people with pulmonary arterial hypertension (PAH). The study includes 20 adults in Japan who have high IL-6 levels and haven't …

This study tests whether whole-body aerobic training (like brisk walking) or isolated leg training (with weights) better improves symptoms and quality of life in people with pulmonary arterial hypertension (PAH). About 45 participants with PAH will be assigned to one of the two e…

This study looks at whether low-resistance exercise (like light strength training) can safely help people with pulmonary arterial hypertension (PAH) feel better and be less frail. About 20 adults with stable PAH will try the program. Researchers will track safety, how well people…

This study looks at whether people with pulmonary arterial hypertension (PAH) have changes in thinking skills like memory and attention. Researchers will compare 30 PAH patients to healthy volunteers using computer-based tests. The goal is to better understand how PAH might affec…

This study was designed to see if a non-invasive finger cuff device could accurately measure how well the heart pumps blood in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). The goal was to replace the usual invasive ri…

This study is collecting blood samples from 550 adults with different types of pulmonary hypertension to measure two proteins, Activin-A and FSTL3. Researchers want to see if these proteins can predict who will need a lung transplant or die within two years. The goal is to find a…

This study looks at nearly 1,200 people with or at risk for pulmonary hypertension (high blood pressure in the lungs). Researchers use many advanced tests to find new ways to classify the disease and identify biomarkers. The goal is to better understand the disease and improve fu…